Teva received Fast Track designation from the U.S. Food and Drug Administration for emrusolmin (TEV-56286), an investigational treatment for Multiple System Atrophy (MSA) in Phase 2 development
Vonvendi is the only recombinant Von Willebrand factor replacement therapy with approved indications in adults and children with VWD
Zydus will work closely with the USFDA to address and resolve the observations in an expeditious manner
Under the terms of this agreement, Synthon will be responsible for obtaining final regulatory approval for its Ozanimod Capsules product
The U.S. FDA issued a Form 483 with five observations
Now integrates with Abbott’s instinct sensor and approved for type 2 diabetes
This is Lupin's first product using proprietary Nanomi's technology and has a 180-day CGT exclusivity
Milrinone is indicated for the short-term intravenous treatment of patients with acute decompensated heart failure
Free cash flow also reached €63 million, representing an 11 percent increase compared to the high benchmark set in 2024
New targeted therapy offers hope for patients with unresectable or metastatic NSCLC harboring HER2 tyrosine kinase domain activating mutations
Subscribe To Our Newsletter & Stay Updated
